Active	Status	Sponsor type	Region	Phase	Filter
6 Active 1 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
linafexor (CS0159) / Cascade Pharma
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH	Completed	2	99	US	CS0159 (Linafexor), placebo	Cascade Pharmaceuticals, Inc, Laboratory Corporation of America	Nonalcoholic Steatohepatitis (NASH)	11/23	11/23
NCT05896124: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)	Recruiting	2	75	RoW	2mg CS0159, Placebo	Cascade Pharmaceuticals, Inc	Primary Biliary Cholangitis (PBC)	10/24	10/24
NCT05896137: CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)	Recruiting	2	50	RoW	CS0159 2mg, Placebo	Cascade Pharmaceuticals, Inc	Primary Sclerosing Cholangitis	12/24	12/24
NCT05624294: Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects	Completed	1	36	RoW	CS0159, Placebo	Cascade Pharmaceuticals, Inc	Primary Biliary Cholangitis	03/23	03/23
NCT06098027: Study of [14C]CS0159 in China Healthy Subjects	Completed	1	6	RoW	[14C]CS0159	Cascade Pharmaceuticals, Inc	Primary Biliary Cholangitis	11/23	11/23
NCT06492330: Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM	Active, not recruiting	N/A	60	RoW	CS0159, CS0159 placebo	Shanghai Jiao Tong University School of Medicine	Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity, Diabetes Mellitus, Type 2	02/25	06/25